Prime Medicine, Inc./$PRME
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Prime Medicine, Inc.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
- Ticker
- $PRME
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 146
- Headquarters
- Cambridge, United States
- Website
- primemedicine.com
PRME Metrics
BasicAdvanced
$642M
-
-$1.09
2.31
-
Price and volume
Market cap
$642M
Beta
2.31
52-week high
$6.65
52-week low
$2.67
Average daily volume
4.1M
Financial strength
Current ratio
3.055
Quick ratio
3
Long term debt to equity
2.6
Total debt to equity
2.825
Profitability
EBITDA (TTM)
-189.122
Gross margin (TTM)
-3,489.52%
Net profit margin (TTM)
-4,613.11%
Operating margin (TTM)
-4,824.94%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-46.52%
Return on equity (TTM)
-373.29%
Valuation
Price to revenue (TTM)
153.441
Price to book
16.07
Price to tangible book (TTM)
16.07
Price to free cash flow (TTM)
-3.984
Free cash flow yield (TTM)
-25.10%
Free cash flow per share (TTM)
-0.906
Growth
Revenue change (TTM)
-17.90%
Earnings per share change (TTM)
-30.88%
3-year earnings per share growth (CAGR)
-22.11%
What the Analysts think about PRME
Analyst ratings (Buy, Hold, Sell) for Prime Medicine, Inc. stock.
Analyst projections of the future price of Prime Medicine, Inc. stock.
Bulls say / Bears say
PM577a has moved from preclinical work into human testing: the first patient has been dosed in a global Phase 1/2 trial for H1069Q Wilson disease. FDA Rare Pediatric Disease designation adds a potential regulatory incentive. (GlobeNewswire)
FDA clearance of PM647's IND brings Prime's second liver-editing programme, for AATD, into clinical development. A binding arbitration decision also confirmed Prime's rights to the candidate and awarded no damages, clearing a legal overhang. (Investing News Network, GlobeNewswire)
PM359 has reported proof-of-concept results in its first two patients and received FDA RMAT designation, giving Prime a second, clinically tested asset and a potentially more direct regulatory route. (Nasdaq, BioPharmaWatch)
Cash, cash equivalents, investments and restricted cash fell to $108.8 million at June 2026 from $191.4 million at year-end, and management expects funding only into 2027. With ongoing losses, the company may need more capital, creating dilution risk. (Nasdaq, StockTitan)
PM577a's first dose and PM647's IND clearance are entry points, not proof of benefit or safety; both are first-in-human programmes, with initial data expected in 2027. Weak or delayed results would undermine the liver-programme growth case. (GlobeNewswire, Investing News Network)
PM359's RMAT designation is not approval: Prime said it was still in discussions with the FDA over a potential BLA, while the reported proof-of-concept covers only two treated patients. The proposed first-half 2027 filing and approval path therefore remain uncertain. (Nasdaq, BioPharmaWatch)
Data summarised monthly by Lightyear AI. Last updated on 12 Oct 2026.
PRME Financial Performance
Revenues and expenses
PRME Earnings Performance
Company profitability
Upcoming events
No upcoming events
PRME News
AllArticlesVideos
Funds containing PRME
AllUSDGBPEUR
Fund name | Fund size | $PRME weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.05% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.05% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.02% |
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.